Natco Pharma Q3 net profit up 12 percent at Rs 217.4 crore
New Delhi: Drug firm Natco Pharma reported an 11.54 percent rise in its consolidated profit after tax at Rs 217.4 crore for the quarter ended December 2017.
The company had posted a profit after tax of Rs 194.9 crore for the corresponding period of the previous fiscal, Natco Pharma said in a BSE filing.
Consolidated total revenues of the company stood at Rs 573.6 crore for the quarter under consideration against Rs 685.1 crore in the same period a year ago.
The company in a separate filing said, its board has declared a second interim dividend of Rs 7 on each equity share of Rs 2 for the year 2017-18.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd